post qualiti result sale oper vs guidanc flat
compani also rais full-year guidanc call oper revenu growth
vs previous ep vs previous
revis larg reflect strength receiv updat lrp target
pipelin may investor day
bax result solid across board
compani revenu beat street forecast
estim reflect oper growth ahead guidanc
out-performance attribut strong demand bax acut busi due flu
increas sale inject pharmaceut advanc surgeri product good
result pd iv solut total compani experienc impact
sale aftermath hurrican maria expect renal sale
oper basi ahead forecast medic deliveri sale
came flat vs forecast notabl show continu strength
 larg volum iv solut abl increas shipment mexico
 go forward compani realloc iv solut certain south american
facil well pharmaceut sale ahead
estim oper cc driven solid number inject
help competit suppli constraint cyclophosphamid sale
clari sale total global nutrit sale flat
line forecast advanc surgeri post sale
estim acut therapi sale
exceed forecast compani saw benefit flu
 lastli sale categori
estim gross margin street forecast
project reflect underli expans bp off-set
foreign exchang hurrican impact increment suppli chain cost
absorb adjust oper margin best us street
oper margin out-performance plu lower tax rate vs
assumpt help drive adjust ep beat assumpt
share street
full-year target constant currenc revenu growth
oper growth vs metric previous compani report
revenu guidanc impli revenu vs previous
ahead street current project ep forecast
rang compar street assumpt
increas compani attribut nine cent out-performance
three cent chang made cyclo sale estim
one cent contribut acquir product given
one quarter revis seem us favor possibl
pleas see page report import disclosur
compani split allow baxter better focu deliv margin expans
top bottom line growth opportun longer term new baxter
hamper low singl digit top line growth trajectori lower oper
ebitda margin profil rel peer earli go clearer path forward
abl acceler top line growth better expect margin expans
opportun could bolster long-term outlook given top-lin margin profil
new baxter believ compani deserv trade premium med tech peer
current valuat keep us market perform
increment share gain sigma
spectrum pump new pd cycler
product updat arti
theranova prismax prismalung
transform bolster
om expans start
level
oper cash flow track grow
new tuck-in bolt-on acquisit
expect gener top-lin
gambro margin synergi deliv
improv ahead expect
om ebitda margin expans
opportun realiz sooner
pipelin opportun acquisit
contribut next five year
gambro margin synergi fail
meet key benchmark improv
om expans come
pipelin fail deliv
 fail produc new top-lin
diversifi global healthcar compani develop medic
devic product use hospit kidney dialysi center nurs home rehabilit
center clinic medic research laboratori patient in-hom use
biopharma solut also chronic acut product offer renal
divis gener total revenu medic product sale
complet acquisit gambro ab largest acquisit histori
bolster renal busi product portfolio juli spun bioscienc
divis form baxalta acquir shire
compon compani outlook appear conserv
renal includ periton dialysi in-cent hemodialysi renal
therapi servic compani anticip growth constant currenc
basi medic deliveri includ sale bax iv therapi infus pump
administr set drug reconstitut devic compani project
cc sale growth previous compris
premix oncolog drug platform inhal anesthesia critic care product
pharmaci compound servic forecast cc sale growth
flat previous nutrit compani anticip sale growth
cc basi advanc surgeri sale product hemostasi tissu seal
adhes prevent project increas year year oper
basi unchang last quarter though mallinckrodt
acquisit constant currenc sale growth rather
contribut assum acut therapi compris bax crrt portfolio
organ support product grow cc basi
previous lastli categori larg contract manufactur servic
expect low single-digit sale declin benefit custom stockpil
order see lower manufactur revenu shire
assumpt unchang respect cash flow anticip gener oper
cash flow roughli previous capital-expenditure
unchang free cash flow approxim
previous look bax revenu guidanc suggest total sale
modestli exce street forecast repres growth
constant currenc basi growth oper basi compani
also guid ep bracket current consensu bax
manufactur facil puerto rico oper pre-hurrican product
level compani expect revenu impact relat post-
sever product launch alway enhanc sale growth
surgic compani recent launch tisseel prima europ
recothrom preveleak renal product begun launch
kaguya system sharesourc japan present nearli japan
end-stag renal diseas patient treat via in-cent hemodialysi thu kaguya
share lot function amia tailor local market face
signific growth outlook patient opt pd pd substanti under-penetrated
japan command market share repres multi-year opportun
compani also meaning launch version nine
sigma spectrum pump platform iter enhanc respect auto-
program featur two-way wireless connect addit sever
launch like new crrt machin new hemofiltr devic along
geograph expans clari acquisit still slate add sale
unchang strengthen compani presenc gener pharmaceut
space indic pipelin impact gener clari start
play theranova compani advanc develop
product two new trial addit recent launch updat iter
oxiri membran use prismaflex system manag sepsi
product help filter remov excess level cytokin endotoxin
inflammatori mediat patient blood repres mean augment
compani presenc acut renal market importantli continu believ
enhanc intern program high-growth compani capac
multibillion-dollar deal like pursu smaller tuck-in acquisit like
recent move product deal carri fewer integr risk
show better return metric identifi enough like turn
share buyback dividend deploy capit
bax lrp target move higher keep long-term stori compel
respect revenu bax lrp sale compound-annual-growth-rate assumpt given compani
product pipelin see growth rate improv recogn
possibl reach compani clearli indic growth
trajectori acceler move past product discontinu
cyclo headwind give credenc view incom statement
compani project adjust oper margin stress
view peak oper margin addit help
mix innov time bax gross margin estim aid
focu drive cost save improv manufactur network
project adjust ep accret assum
clari compani look oper cash flow roughli
expect capital-expenditure see free cash flow year continu
believ feasibl long-term project reduc invest risk
associ stock make outlook attract rel peer struggl
even full-year guidanc like get favor updat outlook
beyond bax investor day next month stock may alreadi bake
above-consensu margin progress dont see loom neg make
long-term stori attract view price target remain averag
forward-year eps- ebitda-driven valuat approach
compani report cowen compani estim
chg medic good gross gross net interest expens expens total expens incom incom tax incom tax incom oper ex intang restructur non-recvr gain incom non-controlling inc inc oper ex-intang restructur non-recur gain share compani report cowen compani estimatest result mm reportedour estim cowen
compani report cowen compani estim
year end decemb end decemb end decemb medic good gross gross net interest expens expens total expens incom incom tax incom tax incom oper ex intang restructur non-recur gain incom non-controlling intang amort inc inc oper ex-intang cowen
compani report cowen compani estim
compani report cowen compani estim
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
compani specif risk includ impact long-act factor viii agent
global share advat franchis limit increas plasma fraction
capac ig franchis time regulatori approv hyq line-extens
bioscienc product develop realiz synergi impact margin
gambro acquisit acquisit exposur emerg market
